Immuron Limited (IMRN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Immuron Limited (IMRN) closed at USD 1.03 on 2026-10-14, a change of -53.2 % over the past year, with a market capitalization of USD 8.31M.

Immuron Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Immuron Limited key figures

Previous close

USD 1.03 (2026-10-14)

1-year change

-53.2 %

Market cap

USD 8.31M

Enterprise value

USD -514,932

P/E ratio (trailing)

-3.12

P/E ratio (forward)

-103.00

EPS (trailing)

-0.33

EPS (forward)

-0.01

PEG ratio

n/a

Price to book

1.05

Revenue growth

7.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.01

Employees

7

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Immuron Limited

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Immuron Limited and compare it with other stocks.